Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Korean Patients
100%
Adalimumab
100%
Moderate-to-severe Psoriasis
100%
Real-world Outcomes
100%
European Quality of Life-5 Dimensions
75%
Psoriasis
50%
Severity Index
50%
Psoriasis Area
50%
Area Index
50%
Psoriasis Severity
50%
Patient-reported Outcomes
50%
Quality of Life
25%
Number of Patients
25%
Patient Satisfaction
25%
Body Surface Area
25%
Index Score
25%
Clinical Trial Registry
25%
Patient Demographics
25%
Well-being
25%
Multicenter Observational Study
25%
Health-related Quality of Life
25%
Quality of Life Improvement
25%
Treatment Efficacy
25%
Short Form 36 (SF-36)
25%
Psychosocial Impact
25%
Treatment Satisfaction
25%
Treatment Burden
25%
Psoriasis Treatment
25%
Health-related QOL
25%
Medicine and Dentistry
Quality of Life
100%
Psoriasis
100%
Adalimumab
100%
Patient-Reported Outcome
33%
Psoriasis Area and Severity Index
33%
Body Surface
16%
Clinical Trial
16%
Patient Satisfaction
16%
Observational Study
16%
Combination Therapy
16%
Patient Population
16%
Short Form 36
16%
Dermatology Life Quality Index
16%
Nursing and Health Professions
Quality of Life
100%
Psoriasis
100%
Adalimumab
100%
Psoriasis Area and Severity Index
33%
Patient-Reported Outcome
33%
Combination Therapy
16%
Surface Area
16%
Patient Satisfaction
16%
Short Form 36
16%
Patient Population
16%
Dermatology Life Quality Index
16%
Pharmacology, Toxicology and Pharmaceutical Science
Psoriasis
100%
Adalimumab
100%
Combination Therapy
14%
Clinical Trial
14%
Observational Study
14%
Psychology
Psoriasis
100%
Quality of Life
85%
Immunology and Microbiology
Adalimumab
100%
Surface Area
25%
Body Surface
25%
Wellbeing
25%